XML 29 R10.htm IDEA: XBRL DOCUMENT v3.25.1

Accounts Payable and Related Party

3 Months Ended

Mar. 31, 2025

Payables and Accruals [Abstract]

Accounts Payable and Related Party

Note 3 – Accounts Payable and Related Party

Accounts payable consists of the following:

Schedule of Accounts Payable 

		As of								As of
		March 31, 2025				%				December 31, 2024				%
Accounts payable to Cytovance, a related party 1		$	600,000				25	%		$	1,183,000				31	%
Accounts payable to University of Minnesota			629,000				26	%			712,000				18	%
Legal services firm			597,000				25	%			1,505,000				39	%
Accounts payable			597,000				25	%			1,505,000				39	%
Other accounts payable			554,000				24	%			453,000				12	%
Total accounts payable		$	2,380,000				100	%		$	3,853,000				100	%

¹ Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock. See Note 7 – Commitments and Contingencies, Significant Agreements.

The details of the Company’s accounts payable to Cytovance were as follows:

Schedule of Accounts Payable to Related Party 

		Three Months Ending
		March 31, 2025				March 31, 2024
		(Unaudited)				(Unaudited)
Beginning balance		$	1,183,000			$	3,515,000
Invoices, net			532,000				269,000
Payments in cash			(268,000	)			(1,800,000	)
Payments in pre-funded warrants, at fair value			(847,000	)			—
Ending balance		$	600,000			$	1,984,000

During the three months ended March 31, 2025, the Company issued pre-funded warrants to purchase up to 326,251 shares of common stock exercisable at $0.0001 per share with a fair value of approximately $847,000 to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued at the market price on the last day of the month during the respective month that the invoices are due.

In March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company’s prior year unpaid fees by approximately $1 million. The Company classified this transaction as other income during the period ended March 31, 2025.

University of Minnesota

See Note 7 – Commitments and Contingencies, Significant Agreements.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 720
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483384/720-30-45-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration